Ramya D. Ravi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ramya D. Ravi has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- D Mohanapriya
Department of Gynecologic Oncology, St John’s Medical College, Bengaluru, Karnataka, India
1 shared publication - Gayatri Ravikumar
Department of Pathology, St. John's Medical College, Bangalore, Karnataka, India
1 shared publication - Geeta Acharya
Department of Gynaecologic Oncology, St. John’s Medical College and Hospital, Bangalore, India
1 shared publication - Kiran Abhijit Kulkarni
St John's Medical College, Bengaluru, India
1 shared publication - Premalatha Siddharta
Department of Gynecologic Oncology, St John’s Medical College, Bengaluru, Karnataka, India
1 shared publication - Vishakha Chandrakant Bidkar
Department of Gynecological Oncology, St. John’s Research Institute, Koramangala, India
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wolters Kluwer Health in Indian Journal of Cancer
- Vol. 62 (1) , 17-22
The prognostic role of omental, ovarian chemotherapy response score and CA125 in predicting survival in patients with tubo-ovarian high-grade serous carcinoma/primary peritoneal carcinoma receiving neoadjuvant chemotherapy
Objective: To assess the role of omental and ovarian chemotherapy response score (CRS) and CA125 as a predictor of prognosis in patients with tubo-ovarian high-grade serous carcinoma (HGSC)/primary peritoneal carcinoma (PPC) receiving neoadjuvant chemotherapy (NACT). In addition, to study the correlation of omental CRS with chemoresistance. Methods: A retrospective record review of patients with tubo-ovarian HGSC/PPC receiving NACT followed by interval debulking surgery (IDS) between January 2012 and May 2020 was done. The slides of the omentum and ovarian tissue of the patients were retrieved and reviewed by a trained pathologist. During analysis, CRS 1 and CRS 2 were merged together for comparison against CRS 3. Results: A total of 44 patients with a mean age of 54 years were included in the study. Among the patients, 29.5%, 38.6%, and 31.8% had a CRS of 1, 2, and 3, respectively, on the omental specimen and 31.8%, 43.2%, and 25% on the ovarian specimen. Median PFS and OS was significantly better with omental CRS 3 (P = < 0.0001 and P = < 0.00065). No significant difference in median OS of patients was noted with ovarian CRS 1, 2, or 3 (P = 0.057); however, the median PFS was significantly better in patients with CRS 3 on ovarian tissue (P = 0.036). Platinum resistance was significantly lower in patients with CRS 3 on omentum (P = 0.001). The value of CA125 post NACT had a significant association with PFS on both univariate and multivariate analyses. There was no statistically significant correlation between CA125 and omental CRS. Conclusion: Omental CRS has a prognostic significance for patients with tubo-ovarian HGSC/PPC receiving NACT and correlates significantly with PFS and OS. Ovarian CRS correlates significantly only with PFS. Post NACT CA125 value had a significant association with PFS.
- 1 January 2025
- Published by Wolters Kluwer Health in Indian Journal of Cancer
- Vol. 62 (1) , 17-22
Open AccessThe prognostic role of omental, ovarian chemotherapy response score and CA125 in predicting survival in patients with tubo-ovarian high-grade serous carcinoma/primary peritoneal carcinoma receiving neoadjuvant chemotherapy
Objective: To assess the role of omental and ovarian chemotherapy response score (CRS) and CA125 as a predictor of prognosis in patients with tubo-ovarian high-grade serous carcinoma (HGSC)/primary peritoneal carcinoma (PPC) receiving neoadjuvant chemotherapy (NACT). In addition, to study the correlation of omental CRS with chemoresistance. Methods: A retrospective record review of patients with tubo-ovarian HGSC/PPC receiving NACT followed by interval debulking surgery (IDS) between January 2012 and May 2020 was done. The slides of the omentum and ovarian tissue of the patients were retrieved and reviewed by a trained pathologist. During analysis, CRS 1 and CRS 2 were merged together for comparison against CRS 3. Results: A total of 44 patients with a mean age of 54 years were included in the study. Among the patients, 29.5%, 38.6%, and 31.8% had a CRS of 1, 2, and 3, respectively, on the omental specimen and 31.8%, 43.2%, and 25% on the ovarian specimen. Median PFS and OS was significantly better with omental CRS 3 (P = < 0.0001 and P = < 0.00065). No significant difference in median OS of patients was noted with ovarian CRS 1, 2, or 3 (P = 0.057); however, the median PFS was significantly better in patients with CRS 3 on ovarian tissue (P = 0.036). Platinum resistance was significantly lower in patients with CRS 3 on omentum (P = 0.001). The value of CA125 post NACT had a significant association with PFS on both univariate and multivariate analyses. There was no statistically significant correlation between CA125 and omental CRS. Conclusion: Omental CRS has a prognostic significance for patients with tubo-ovarian HGSC/PPC receiving NACT and correlates significantly with PFS and OS. Ovarian CRS correlates significantly only with PFS. Post NACT CA125 value had a significant association with PFS.